Tonix Pharmaceuticals director Dr. Daniel Goodman will not stand for reelection at 2022 annual meeting

Tonix Pharmaceuticals Holding Corp.

Dr. Daniel Goodman notified Tonix on Feb 16, 2022, of his decision not to stand for reelection.
He will continue as director and retain committee memberships through the 2022 Annual Meeting.
No replacement director has been announced; the 2022 Annual Meeting date is not specified.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Daniel Goodman

Director

TNXP · Tonix Pharmaceuticals Holding Corp.

Filed: February 18, 2022, 6:59 PM ET

Dr. Daniel Goodman provided notice to Tonix Pharmaceuticals Holding Corp. (the “Company”) of his intention not to stand for reelection at the Company’s 2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Goodman departed as Director at Tonix Pharmaceuticals Holding Corp..

Action: not stand for reelection
Role: Director

Exact text from the filing

Dr. Daniel Goodman provided notice to Tonix Pharmaceuticals Holding Corp. (the “Company”) of his intention not to stand for reelection at the Company’s 2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”).

View on SEC.gov

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001387131-22-002256

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.